HR 6994119th CongressIn Committee

Mental Health TALK SAFE Act of 2026

Standard Summary
Balanced plain-English summary

This bill amends the Controlled Substances Act to allow certain controlled substances to be prescribed through telehealth after at least one telehealth evaluation, including approved mental health medications and medications for opioid use disorder. It defines telehealth entities and practitioners, sets corporate and compliance standards, bars pharmacists from refusing prescriptions solely because they were issued via telehealth unless they try to validate concerns, waives extra DEA state registrations in some telehealth cases, and preempts conflicting state rules while providing interstate licensure treatment for psychiatrists.

Key Points

  • 1Creates a telehealth pathway for prescribing approved mental health controlled substances and opioid use disorder medications after at least one telehealth evaluation.
  • 2Establishes detailed definitions and operating requirements for telehealth entities, practitioners, and exempt entities.
  • 3Requires pharmacists to attempt validation before refusing a telehealth-issued controlled substance prescription and imposes civil penalties for violations.
  • 4Allows certain telehealth practitioners to use the entity address for DEA registration and avoid additional state registrations in some cases.
  • 5Preempts conflicting state laws and addresses interstate psychiatrist licensure and liability coverage.

Impact Areas

Psychiatrists and psychiatric mental health advanced practice nursesTelehealth companies and mental health providersPharmacists and pharmaciesPatients needing mental health or opioid use disorder treatmentState medical licensing and DEA registration systems
Generated by deepseek/deepseek-v4.1-flash-1017Nov 18, 2026